Library / Peptides / Gut & Inflammation / KPV

Theoretical · Grade C

KPV

KPV (Lys-Pro-Val, alpha-MSH Fragment 11-13)

Evidence

Theoretical

Route

Oral, Subcutaneous injection, or Topical

Frequency

1-2x daily

Mechanism.

KPV is a naturally occurring tripeptide (Lysine-Proline-Valine) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains the potent inflammation-modulating properties of the parent hormone without its melanogenic (skin-darkening) effects. KPV has been studied primarily in preclinical models for inflammatory bowel disease, skin inflammation, and wound healing.

Alpha-MSH is like a Swiss Army knife with many tools — inflammation-modulating action, skin tanning, appetite effects. KPV is just the inflammation-modulating blade extracted from that knife, doing one job very well without the other effects.

Mechanism · technical

KPV exerts inflammation-modulating effects primarily by entering cells and directly interacting with inflammatory signaling pathways. It inhibits NF-kB activation, reducing the transcription of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6). KPV has been shown to penetrate intestinal epithelial cells and interact with intracellular inflammatory mediators. Unlike full-length alpha-MSH, KPV does not significantly activate melanocortin receptors responsible for pigmentation, allowing it to deliver inflammation-modulating benefits without skin darkening.

Part 02 · Dosing & administration

How it's taken.

Values below describe how KPV has been administered in published trials and labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose

200-500 mcg

Oral, Subcutaneous injection, or Topical · 1-2x daily

Duration

4-8 weeks typical cycle

C-terminal fragment of alpha-MSH (11-13). Inflammation-modulating without melanogenic effects. Oral/capsule form often used for GI applications. Not FDA-approved; published research protocols.

Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator

Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Reported side effects

KPV has shown a very favorable safety profile in preclinical studies with no significant toxicity reported. Human safety data is extremely limited. Theoretical side effects may include injection site reactions and mild GI symptoms with oral use. No known serious adverse effects have been identified in the published literature.

Absolute · do not use

Active systemic infection (may suppress needed inflammatory response)

Pregnancy or breastfeeding

Children under 18

Known hypersensitivity to KPV, alpha-MSH fragments, or any component

Interactions

Immunosuppressants (tacrolimus, cyclosporine, biologics)

Additive immunosuppressive/inflammation-modulating effects; may increase infection risk

Moderate

NSAIDs

Additive inflammation-modulating effects; generally favorable but monitor for excessive immune suppression in vulnerable patients

Minor

TNF inhibitors (adalimumab, infliximab)

KPV inhibits NF-kB and TNF pathways; additive immunosuppression risk

Moderate

Labs to monitor

CRP / ESR

Baseline and monthly

Track inflammatory markers (primary indication is inflammation-modulating)

CMP (Comprehensive Metabolic Panel)

Baseline and every 3 months

Liver and kidney function

CBC with Differential

Baseline and every 3 months

Monitor immune parameters

Fecal Calprotectin

Baseline and monthly

If used for GI inflammation/IBD

Part 04 · Research log

Every study we cite.

Each study with its published finding and a plain-language note on limitations or funding.

2008

KPV peptide suppresses colitis in animal models

Oral KPV reduced colonic inflammation and TNF-alpha in murine colitis models

Preclinical; well-designed animal study

PMID 18200040 ↗

2006

Alpha-MSH fragments as inflammation-modulating agents

KPV retained inflammation-modulating activity of alpha-MSH without melanocortin receptor-mediated side effects

In vitro and in vivo mechanistic studies

Part 05 · Cost & access

Where you can get it.

Regulatory status

KPV is not FDA-approved for any indication. It is available through some compounding pharmacies with a prescription and as a research peptide. It has no formal regulatory designation and remains primarily investigational.

The Peptide Column takes no affiliate commission from any source.

Part 06 · Your appointment

Questions to bring.

Is KPV appropriate for my inflammatory condition given the limited human data?

What is the difference between oral, topical, and injectable KPV?

How does KPV compare to established inflammation-modulating treatments for my condition?

Are there any drug interactions I should be aware of with KPV?

What would a reasonable trial period look like to evaluate KPV's effects?

Is there clinical trial data in humans supporting KPV for gut inflammation?